Reviewing Aquestive Therapeutics Inc. (AQST)’s and resTORbio Inc. (NASDAQ:TORC)’s results

We will be comparing the differences between Aquestive Therapeutics Inc. (NASDAQ:AQST) and resTORbio Inc. (NASDAQ:TORC) as far as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aquestive Therapeutics Inc. 62.80M 2.43 58.10M -2.81 0.00
resTORbio Inc. N/A 0.00 54.91M -2.06 0.00

Table 1 demonstrates Aquestive Therapeutics Inc. and resTORbio Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Aquestive Therapeutics Inc. (NASDAQ:AQST) and resTORbio Inc. (NASDAQ:TORC)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Aquestive Therapeutics Inc. -92.52% 0% 0%
resTORbio Inc. 0.00% -67.6% -50.1%

Liquidity

3.6 and 3.4 are the respective Current Ratio and a Quick Ratio of Aquestive Therapeutics Inc. Its rival resTORbio Inc.’s Current and Quick Ratios are 14.5 and 14.5 respectively. resTORbio Inc. has a better chance of clearing its pay short and long-term debts than Aquestive Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Aquestive Therapeutics Inc. and resTORbio Inc. are owned by institutional investors at 65.2% and 43.4% respectively. Insiders owned roughly 9.8% of Aquestive Therapeutics Inc.’s shares. On the other hand, insiders owned about 55.61% of resTORbio Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aquestive Therapeutics Inc. -3.38% -53.66% -55.54% 0% 0% -48.29%
resTORbio Inc. -3.52% 5.79% 2.61% 24.26% 0% -25.36%

For the past year resTORbio Inc. has weaker performance than Aquestive Therapeutics Inc.

Summary

resTORbio Inc. beats on 5 of the 9 factors Aquestive Therapeutics Inc.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.